MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-03-2022
Codiak BioSciences Retained Earnings 2011-2025 | CDAK
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Codiak BioSciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -325 M | -288 M | -193 M | -109 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -109 M | -325 M | -229 M |
Quarterly Retained Earnings Codiak BioSciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -359 M | - | -333 M | -325 M | -342 M | -320 M | -298 M | -288 M | -288 M | -288 M | -288 M | -193 M | -193 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -193 M | -359 M | -293 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.28 B | $ 4.76 | -0.69 % | $ 790 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-903 M | $ 3.03 | -0.33 % | $ 234 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-972 M | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-166 M | $ 0.22 | 23.77 % | $ 479 M |  Israel |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 1.17 | - | $ 6.38 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Celldex Therapeutics
CLDX
|
-1.56 B | $ 26.37 | -1.71 % | $ 1.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectar Biosciences
CLRB
|
-203 M | $ 2.55 | -7.79 % | $ 31.2 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 208.21 | -2.16 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
-248 M | $ 0.59 | -36.45 % | $ 163 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.16 | 2.1 % | $ 7.6 B |  Australia |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
-352 M | $ 1.22 | -3.94 % | $ 1.8 M | USA |
 |
Athersys
ATHX
|
-583 M | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-1.02 B | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 94.44 | -0.62 % | $ 27.2 B | Germany |
 |
Dynavax Technologies Corporation
DVAX
|
-903 M | $ 15.38 | - | $ 2 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
569 M | $ 26.88 | 0.26 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.61 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
128 M | $ 9.54 | 0.65 % | $ 140 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-104 M | $ 16.96 | -0.16 % | $ 435 M | USA |
 |
Evogene Ltd.
EVGN
|
-179 M | $ 1.01 | -3.81 % | $ 27.9 M | Israel |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |
 |
Exelixis
EXEL
|
-98.6 M | $ 46.29 | -0.47 % | $ 13.4 B | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
-491 M | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
812 M | $ 585.38 | -0.98 % | $ 44.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M | Israel |
|
Foghorn Therapeutics
FHTX
|
-558 M | $ 5.37 | -0.56 % | $ 295 M | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.47 | -2.57 % | $ 15.5 M | USA |
 |
AstraZeneca PLC
AZN
|
5.3 B | $ 92.54 | 0.1 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 12.42 | 0.36 % | $ 818 M | USA |